Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Differential Expression of CD43, CD81, and CD200 in Classic Versus Variant Hairy Cell Leukemia.

Salem DA, Scott D, McCoy CS, Liewehr DJ, Venzon DJ, Arons E, Kreitman RJ, Stetler-Stevenson M, Yuan CM.

Cytometry B Clin Cytom. 2019 May 11. doi: 10.1002/cyto.b.21785. [Epub ahead of print]

PMID:
31077558
2.

Isolating pulmonary microvascular endothelial cells ex vivo: Implications for pulmonary arterial hypertension, and a caution on the use of commercial biomaterials.

Wertheim BM, Lin YD, Zhang YY, Samokhin AO, Alba GA, Arons E, Yu PB, Maron BA.

PLoS One. 2019 Feb 27;14(2):e0211909. doi: 10.1371/journal.pone.0211909. eCollection 2019.

3.

Generation of antibody-based therapeutics targeting the Idiotype of B-cell Malignancies.

Weiss E, Sarnovsky R, Ho M, Arons E, Kreitman R, Angelus E, Antignani A, FitzGerald D.

Antib Ther. 2019 Jan;2(1):1-10. doi: 10.1093/abt/tby012. Epub 2018 Dec 27.

4.

NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension.

Samokhin AO, Stephens T, Wertheim BM, Wang RS, Vargas SO, Yung LM, Cao M, Brown M, Arons E, Dieffenbach PB, Fewell JG, Matar M, Bowman FP, Haley KJ, Alba GA, Marino SM, Kumar R, Rosas IO, Waxman AB, Oldham WM, Khanna D, Graham BB, Seo S, Gladyshev VN, Yu PB, Fredenburgh LE, Loscalzo J, Leopold JA, Maron BA.

Sci Transl Med. 2018 Jun 13;10(445). pii: eaap7294. doi: 10.1126/scitranslmed.aap7294.

5.

Update on hairy cell leukemia.

Kreitman RJ, Arons E.

Clin Adv Hematol Oncol. 2018 Mar;16(3):205-215. Review.

6.

Up-regulation of the mammalian target of rapamycin complex 1 subunit Raptor by aldosterone induces abnormal pulmonary artery smooth muscle cell survival patterns to promote pulmonary arterial hypertension.

Aghamohammadzadeh R, Zhang YY, Stephens TE, Arons E, Zaman P, Polach KJ, Matar M, Yung LM, Yu PB, Bowman FP, Opotowsky AR, Waxman AB, Loscalzo J, Leopold JA, Maron BA.

FASEB J. 2016 Jul;30(7):2511-27. doi: 10.1096/fj.201500042. Epub 2016 Mar 22.

7.

Impact of telomere length on survival in classic and variant hairy cell leukemia.

Arons E, Zhou H, Edelman DC, Gomez A, Steinberg SM, Petersen D, Wang Y, Meltzer PS, Kreitman RJ.

Leuk Res. 2015 Dec;39(12):1360-6. doi: 10.1016/j.leukres.2015.09.015. Epub 2015 Sep 24.

8.

Upregulation of steroidogenic acute regulatory protein by hypoxia stimulates aldosterone synthesis in pulmonary artery endothelial cells to promote pulmonary vascular fibrosis.

Maron BA, Oldham WM, Chan SY, Vargas SO, Arons E, Zhang YY, Loscalzo J, Leopold JA.

Circulation. 2014 Jul 8;130(2):168-79. doi: 10.1161/CIRCULATIONAHA.113.007690. Epub 2014 Apr 28.

9.

Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome.

Arons E, Adams S, Venzon DJ, Pastan I, Kreitman RJ.

Br J Haematol. 2014 Sep;166(5):729-38. doi: 10.1111/bjh.12956. Epub 2014 Jun 13.

10.

The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.

Sivina M, Kreitman RJ, Arons E, Ravandi F, Burger JA.

Br J Haematol. 2014 Jul;166(2):177-88. doi: 10.1111/bjh.12867. Epub 2014 Apr 2.

11.

Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia.

Kreitman RJ, Wilson W, Calvo KR, Arons E, Roth L, Sapolsky J, Zhou H, Raffeld M, Stetler-Stevenson M.

Clin Cancer Res. 2013 Dec 15;19(24):6873-81. doi: 10.1158/1078-0432.CCR-13-1752. Epub 2013 Nov 25.

12.

High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias.

Waterfall JJ, Arons E, Walker RL, Pineda M, Roth L, Killian JK, Abaan OD, Davis SR, Kreitman RJ, Meltzer PS.

Nat Genet. 2014 Jan;46(1):8-10. doi: 10.1038/ng.2828. Epub 2013 Nov 17.

13.

Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.

Burotto M, Stetler-Stevenson M, Arons E, Zhou H, Wilson W, Kreitman RJ.

Clin Cancer Res. 2013 Nov 15;19(22):6313-21. doi: 10.1158/1078-0432.CCR-13-1848. Epub 2013 Oct 4.

14.

Improved pulmonary vascular reactivity and decreased hypertrophic remodeling during nonhypercapnic acidosis in experimental pulmonary hypertension.

Christou H, Reslan OM, Mam V, Tanbe AF, Vitali SH, Touma M, Arons E, Mitsialis SA, Kourembanas S, Khalil RA.

Am J Physiol Lung Cell Mol Physiol. 2012 May 1;302(9):L875-90. doi: 10.1152/ajplung.00293.2011. Epub 2012 Jan 27.

15.

Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.

Xi L, Arons E, Navarro W, Calvo KR, Stetler-Stevenson M, Raffeld M, Kreitman RJ.

Blood. 2012 Apr 5;119(14):3330-2. doi: 10.1182/blood-2011-09-379339. Epub 2011 Dec 30.

16.

Molecular variant of hairy cell leukemia with poor prognosis.

Arons E, Kreitman RJ.

Leuk Lymphoma. 2011 Jun;52 Suppl 2:99-102. doi: 10.3109/10428194.2011.565841.

PMID:
21599610
17.

Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia.

Kreitman RJ, Arons E, Stetler-Stevenson M, Fitzgerald DJ, Wilson WH, Pastan I.

Leuk Lymphoma. 2011 Jun;52 Suppl 2:82-6. doi: 10.3109/10428194.2011.565843. Review.

PMID:
21599609
18.

Response of hairy cell leukemia to bendamustine.

Kreitman RJ, Arons E, Stetler-Stevenson M, Miller KB.

Leuk Lymphoma. 2011 Jun;52(6):1153-6. doi: 10.3109/10428194.2011.562575. Epub 2011 Apr 4. No abstract available.

PMID:
21463128
19.

Evidence of canonical somatic hypermutation in hairy cell leukemia.

Arons E, Roth L, Sapolsky J, Suntum T, Stetler-Stevenson M, Kreitman RJ.

Blood. 2011 May 5;117(18):4844-51. doi: 10.1182/blood-2010-11-316737. Epub 2011 Mar 2.

20.

Heme oxygenase-1 does not mediate the effects of extracellular acidosis on vascular smooth muscle cell proliferation, migration, and susceptibility to apoptosis.

Brenninkmeijer L, Kuehl C, Geldart AM, Arons E, Christou H.

J Vasc Res. 2011;48(4):285-96. doi: 10.1159/000321555. Epub 2011 Jan 26.

21.

REM-related obstructive sleep apnea: the effect of body position.

Oksenberg A, Arons E, Nasser K, Vander T, Radwan H.

J Clin Sleep Med. 2010 Aug 15;6(4):343-8.

22.

Severe obstructive sleep apnea: sleepy versus nonsleepy patients.

Oksenberg A, Arons E, Nasser K, Shneor O, Radwan H, Silverberg DS.

Laryngoscope. 2010 Mar;120(3):643-8. doi: 10.1002/lary.20758.

PMID:
19941283
23.

Impaired vasoconstriction and nitric oxide-mediated relaxation in pulmonary arteries of hypoxia- and monocrotaline-induced pulmonary hypertensive rats.

Mam V, Tanbe AF, Vitali SH, Arons E, Christou HA, Khalil RA.

J Pharmacol Exp Ther. 2010 Feb;332(2):455-62. doi: 10.1124/jpet.109.160119. Epub 2009 Nov 13.

24.

VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy.

Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ.

Blood. 2009 Nov 19;114(21):4687-95. doi: 10.1182/blood-2009-01-201731. Epub 2009 Sep 10.

25.

[The significance of body posture on breathing abnormalities during sleep: data analysis of 2077 obstructive sleep apnea patients].

Oksenberg A, Arons E, Greenberg-Dotan S, Nasser K, Radwan H.

Harefuah. 2009 May;148(5):304-9, 351, 350. Hebrew.

PMID:
19630360
26.
27.

PRAME expression in hairy cell leukemia.

Arons E, Suntum T, Margulies I, Yuan C, Stetler-Stevenson M, Kreitman RJ.

Leuk Res. 2008 Sep;32(9):1400-6. doi: 10.1016/j.leukres.2007.12.010. Epub 2008 Mar 4.

28.

Validation of the BiteStrip screener for sleep bruxism.

Shochat T, Gavish A, Arons E, Hadas N, Molotsky A, Lavie P, Oksenberg A.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Sep;104(3):e32-9. Epub 2007 Jul 6.

PMID:
17618147
29.

Immunoglobulin light chain repertoire in hairy cell leukemia.

Arons E, Suntum T, Sunshine J, Stetler-Stevenson M, Kreitman RJ.

Leuk Res. 2007 Sep;31(9):1231-6. Epub 2007 Apr 25.

PMID:
17462732
30.

Positional therapy for obstructive sleep apnea patients: A 6-month follow-up study.

Oksenberg A, Silverberg D, Offenbach D, Arons E.

Laryngoscope. 2006 Nov;116(11):1995-2000.

PMID:
17075418
31.
32.

Somatic hypermutation and VH gene usage in hairy cell leukaemia.

Arons E, Sunshine J, Suntum T, Kreitman RJ.

Br J Haematol. 2006 Jun;133(5):504-12.

PMID:
16681637
33.

Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction.

Arons E, Margulies I, Sorbara L, Raffeld M, Stetler-Stevenson M, Pastan I, Kreitman RJ.

Clin Cancer Res. 2006 May 1;12(9):2804-11.

34.

Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy.

Arons E, Sorbara L, Raffeld M, Stetler-Stevenson M, Steinberg SM, Liewehr DJ, Pastan I, Kreitman RJ.

Cancer Immunol Immunother. 2006 Sep;55(9):1100-10. Epub 2005 Nov 26.

PMID:
16311729
35.
36.

Cheyne-Stokes respiration during sleep: a possible effect of body position.

Oksenberg A, Arons E, Snir D, Radwan H, Soroker N.

Med Sci Monit. 2002 Jul;8(7):CS61-5.

37.

Rapid Eye Movement (REM) sleep behavior disorder: a sleep disturbance affecting mainly older men.

Oksenberg A, Radwan H, Arons E, Hoffenbach D, Behroozi B.

Isr J Psychiatry Relat Sci. 2002;39(1):28-35.

PMID:
12013707
38.

Phasic activities of rapid eye movement sleep in vegetative state patients.

Oksenberg A, Gordon C, Arons E, Sazbon L.

Sleep. 2001 Sep 15;24(6):703-6.

PMID:
11560184
39.

Organization and functional analysis of the mouse transporter associated with antigen processing 2 promoter.

Arons E, Kunin V, Schechter C, Ehrlich R.

J Immunol. 2001 Mar 15;166(6):3942-51.

40.

Sleep-related erections in vegetative state patients.

Oksenberg A, Arons E, Sazbon L, Mizrahi A, Radwan H.

Sleep. 2000 Nov 1;23(7):953-7.

PMID:
11083604
42.
43.

Avoiding the supine position during sleep lowers 24 h blood pressure in obstructive sleep apnea (OSA) patients.

Berger M, Oksenberg A, Silverberg DS, Arons E, Radwan H, Iaina A.

J Hum Hypertens. 1997 Oct;11(10):657-64.

PMID:
9400908
44.
45.

High-resolution optical chirped pulse gating.

Arons E, Leith EN, Tien AC, Wagner R.

Appl Opt. 1997 Apr 20;36(12):2603-8.

PMID:
18253250
46.

Contribution of the intracellular domain of murine Fc-gamma receptor type IIB1 to its tumor-enhancing potential.

Zusman T, Lisansky E, Arons E, Anavi R, Bonnerot C, Sautes C, Fridman WH, Witz IP, Ran M.

Int J Cancer. 1996 Oct 9;68(2):219-27.

47.

Improved imagery through scattering materials by quasi-Fourier-synthesis holography.

Arons E, Dilworth D.

Appl Opt. 1996 Jun 10;35(17):3104-8. doi: 10.1364/AO.35.003104.

PMID:
21102687
48.

Lensless imaging by spatial Fourier synthesis holography.

Arons E, Dilworth D.

Appl Opt. 1996 Feb 10;35(5):777-81. doi: 10.1364/AO.35.000777.

PMID:
21069067
49.

Analysis of Fourier synthesis holography for imaging through scattering materials.

Arons E, Dilworth D.

Appl Opt. 1995 Apr 10;34(11):1841-7. doi: 10.1364/AO.34.001841.

PMID:
21037729
50.

Nonscanning confocal ranging system.

Sun PC, Arons E.

Appl Opt. 1995 Mar 1;34(7):1254-61. doi: 10.1364/AO.34.001254.

PMID:
21037656

Supplemental Content

Support Center